推进阿尔茨海默病的联合治疗。
Advancing combination therapy for Alzheimer's disease.
作者信息
Salloway Stephen P, Sevingy Jeff, Budur Kumar, Pederson Jan Torleif, DeMattos Ronald B, Von Rosenstiel Philipp, Paez Antonio, Evans Rebecca, Weber Christopher J, Hendrix James A, Worley Susan, Bain Lisa J, Carrillo Maria C
机构信息
Brown University Providence Rhode Island USA.
Prevail Therapeutics New York New York USA.
出版信息
Alzheimers Dement (N Y). 2020 Oct 7;6(1):e12073. doi: 10.1002/trc2.12073. eCollection 2020.
Abstract
The study of Alzheimer's disease (AD) has led to an increased understanding of the multiple pathologies and pathways of the disease. As such, it has been proposed that AD and its various stages might be most effectively treated with a combination approach rather than a single therapy; however, combination approaches present many challenges that include limitations of non-clinical models, complexity of clinical trial design, and unclear regulatory requirements. The Alzheimer's Association Research Roundtable meeting on May 7-8, 2018, discussed the approaches and challenges of combination therapy for AD. Experts in the field (academia, industry, and government) provided perspectives that may help establish a path forward for the development of new combination therapies.
摘要
对阿尔茨海默病（AD）的研究增进了人们对该疾病多种病理和发病途径的理解。因此，有人提出，采用联合治疗方法而非单一疗法可能最有效地治疗AD及其各个阶段；然而，联合治疗方法存在许多挑战，包括非临床模型的局限性、临床试验设计的复杂性以及监管要求不明确。2018年5月7日至8日举行的阿尔茨海默病协会研究圆桌会议讨论了AD联合治疗的方法和挑战。该领域的专家（学术界、产业界和政府）提供了一些观点，可能有助于为新联合疗法的开发指明前进方向。
相似文献
1
Advancing combination therapy for Alzheimer's disease.
Alzheimers Dement (N Y). 2020 Oct 7;6(1):e12073. doi: 10.1002/trc2.12073. eCollection 2020.
2
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.
3
Charting a path toward combination therapy for Alzheimer's disease.
Expert Rev Neurother. 2015 Jan;15(1):107-13. doi: 10.1586/14737175.2015.995168. Epub 2014 Dec 26.
4
Tau: From research to clinical development.
Alzheimers Dement. 2016 Oct;12(10):1033-1039. doi: 10.1016/j.jalz.2016.03.018. Epub 2016 May 4.
5
Building a roadmap for developing combination therapies for Alzheimer's disease.
Expert Rev Neurother. 2015 Mar;15(3):327-33. doi: 10.1586/14737175.2015.996551.
6
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.
Alzheimers Dement (N Y). 2017 Aug 5;3(3):440-449. doi: 10.1016/j.trci.2017.07.001. eCollection 2017 Sep.
7
Combination Therapy in Alzheimer's Disease: Is It Time?
J Alzheimers Dis. 2022;87(4):1433-1449. doi: 10.3233/JAD-215680.
8
Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease.
Alzheimers Dement (N Y). 2020 Oct 12;6(1):e12090. doi: 10.1002/trc2.12090. eCollection 2020.
9
Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.
Alzheimers Dement. 2013 Sep;9(5):594-601. doi: 10.1016/j.jalz.2013.05.1762.
10
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13.
引用本文的文献
1
Prevalence and risk factors of cerebral microhemorrhages and superficial siderosis in cognitively unimpaired older adults: analysis from the CHARIOT-PRO SubStudy.
Alzheimers Dement. 2025 Aug;21(8):e70594. doi: 10.1002/alz.70594.
2
A manifesto for Alzheimer's disease drug discovery in the era of disease-modifying therapies.
Mol Neurodegener. 2025 Aug 6;20(1):88. doi: 10.1186/s13024-025-00872-7.
3
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.
Alzheimers Dement. 2025 Aug;21(8):e70536. doi: 10.1002/alz.70536.
4
Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD).
Alzheimers Dement. 2025 Jul;21(7):e70441. doi: 10.1002/alz.70441.
5
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life.
Acta Neuropathol Commun. 2025 May 29;13(1):121. doi: 10.1186/s40478-025-02022-y.
6
Interplay Between Vascular Dysfunction and Neurodegenerative Pathology: New Insights into Molecular Mechanisms and Management.
Biomolecules. 2025 May 13;15(5):712. doi: 10.3390/biom15050712.
7
Immune Modulation in Alzheimer's Disease: From Pathogenesis to Immunotherapy.
Cells. 2025 Feb 12;14(4):264. doi: 10.3390/cells14040264.
8
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting.
Alzheimers Dement (N Y). 2025 Feb 11;11(1):e70038. doi: 10.1002/trc2.70038. eCollection 2025 Jan-Mar.
9
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation.
J Prev Alzheimers Dis. 2025 Jan;12(1):100001. doi: 10.1016/j.tjpad.2024.100001. Epub 2025 Jan 1.
10
Alzheimer's disease drug development in an evolving therapeutic landscape.
Alzheimers Dement (N Y). 2024 Nov 30;10(4):e70015. doi: 10.1002/trc2.70015. eCollection 2024 Oct-Dec.
本文引用的文献
1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Cell. 2019 Oct 3;179(2):312-339. doi: 10.1016/j.cell.2019.09.001. Epub 2019 Sep 26.
2
Elucidating Tau function and dysfunction in the era of cryo-EM.
J Biol Chem. 2019 Jun 14;294(24):9316-9325. doi: 10.1074/jbc.REV119.008031. Epub 2019 May 14.
3
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.
Neurobiol Aging. 2019 Mar;75:42-50. doi: 10.1016/j.neurobiolaging.2018.10.011. Epub 2018 Oct 13.
4
The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: More Similar Than Different.
JAMA. 2018 Nov 6;320(17):1749-1750. doi: 10.1001/jama.2018.16755.
5
Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.
JAMA Neurol. 2018 Sep 1;75(9):1124-1131. doi: 10.1001/jamaneurol.2018.1123.
6
Tau Kinetics in Neurons and the Human Central Nervous System.
Neuron. 2018 Mar 21;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015.
7
Heat Shock Proteins and Autophagy Pathways in Neuroprotection: from Molecular Bases to Pharmacological Interventions.
Int J Mol Sci. 2018 Jan 22;19(1):325. doi: 10.3390/ijms19010325.
8
Practical considerations for choosing a mouse model of Alzheimer's disease.
Mol Neurodegener. 2017 Dec 22;12(1):89. doi: 10.1186/s13024-017-0231-7.
9
Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer.
J Prev Alzheimers Dis. 2016;3(3):164-172. doi: 10.14283/jpad.2015.85.
10
APP mouse models for Alzheimer's disease preclinical studies.
EMBO J. 2017 Sep 1;36(17):2473-2487. doi: 10.15252/embj.201797397. Epub 2017 Aug 1.
Zotero 插件